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Epidemiological studies, clinical observations, and advances in molecular genetics are 
contributing to the understanding of the etiology of congenital heart defects (CHDs). 
Several phenotype–genotype correlation studies have suggested that specific morpho-
genetic mechanisms put in motion by genes can result in a specific cardiac phenotype. 
The use of new technologies has increased the possibility of identification of new genes 
and chromosomal loci in syndromic and non-syndromic CHDs. There are a number of 
methods available for genetic research studies of CHDs, including cytogenetic analysis, 
linkage and association studies, copy number variation (CNV) and DNA micro-array 
analysis, and whole exome sequencing. The altered dosage of contiguous genes 
included inside CNVs can produce new syndromic CHDs, so that several different new 
genomic conditions have been identified. These include duplication 22q11.2 syndrome, 
distal 22q11.2 deletion syndrome, deletion and duplication 1q21.1, and deletion 1p36 
syndrome. Molecular techniques such as whole exome sequencing have lead to the 
identification of new genes for monogenic syndromes with CHD, as for example in 
Adams–Oliver, Noonan, and Kabuki syndrome. The variable expressivity and reduced 
penetrance of CHDs in genetic syndromes is likely influenced by genetic factors, and 
several studies have been performed showing the involvement of modifier genes. It is 
not easy to define precisely the genetic defects underlying non-syndromic CHDs, due 
to the genetic and clinical heterogeneity of these malformations. Recent experimental 
studies have identified multiple CNVs contributing to non-syndromic CHD. The number 
of identified genes for non-syndromic CHDs is at this time limited, and each of the iden-
tified genes has been shown to be implicated only in a small proportion of CHD. The 
application of new technologies to specific cases of CHD and pedigrees with familial 
recurrence and filtering genes mapping in CNV regions can probably in the future add 
knowledge about new genes for non-syndromic CHDs.
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iNTRODUCTiON
Epidemiological studies, clinical observations, and advances in molecular genetics are contributing 
to the understanding of the etiology of congenital heart defects (CHDs). The majority of CHDs are 
occurring as isolated malformations, while approximately 25–30% of them are associated with ext-
racardiac anomalies, in the setting of large or submicroscopic chromosomal anomalies, Mendelian 
disorders, and malformation associations (1–3). Some types of CHD, such as atrioventricular canal 
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defect (AVCD) and interrupted aortic arch (IAA), are more 
frequently found in association with genetic syndromes, whereas 
other types are prevalently isolated defects (tricuspid atresia, 
transposition of the great arteries, and pulmonary atresia). Several 
phenotype–genotype correlation studies have suggested that 
specific morphogenetic mechanisms put in motion by genes can 
result in a specific cardiac phenotype (4). Clinical implications 
are resulting from these studies, since distinct cardiac anatomic 
subtypes may help in suggesting accurate diagnoses, which can be 
confirmed by molecular testing.
It should be considered that it is not easy to define precisely the 
genetic defects underlying CHDs, particularly non-syndromic 
types, due to the genetic and clinical heterogeneity of these 
malformations. Multiple parallel approaches are needed for the 
exploration of the potential loci etiologically related to CHDs. 
Rapid advances in genetic technologies have substantially 
improved the possibility to detect new genes and chromosomal 
regions for CHDs. There are a number of methods available for 
genetic research studies of CHDs, including cytogenetic analysis, 
linkage and association studies, copy number variation (CNV) 
and DNA micro-array analysis, and whole exome sequencing. 
The use of new technologies has increased the possibility of 
identification of new genes and chromosomal loci in syndromic 
and non-syndromic CHDs.
SYNDROMiC CHDs
The 30% of patients with syndromic CHD can be affected by chro-
mosomal anomalies, Mendelian syndromes, and non-Mendelian 
associations.
Classic chromosome anomalies detectable by normal standard 
karyotype include trisomy 21 (Down syndrome), trisomy 13 
(Patau syndrome), and trisomy 18 (Edwards syndrome), mono-
somy X (Turner syndrome), deletion 8p23.1, and terminal dele-
tion 4p. Each chromosomal anomaly is preferentially associated 
with specific types of CHDs, as occurring for AVCD and Down 
syndrome or aortic coarctation and Turner syndrome.
The more frequent chromosomal syndromes linked to sub-
microscopic anomalies detectable by Fluorescent in situ hybridi-
zation analysis (FISH) or arrayCGH are the 22q11.2 deletion 
(DiGeorge/velocardiofacial) with conotruncal heart defects and 
Williams syndromes with supravalvular aortic stenosis.
Monogenic syndromes characteristically associated with CHD 
are represented by Noonan syndrome and other RASopathies, 
Alagille, Kabuki, Ellis–van Creveld, Holt–Oram, CHARGE, 
Marfan, and Cornelia de Lange syndromes. Malformation asso-
ciations are including VACTERL, Goldenhar (oculo-auriculo-
vertebral spectrum), and Cantrell.
New CHROMOSOMAL SYNDROMeS 
wiTH CHD
The development of molecular technologies is leading to the 
identification of new subchromosomal changes in genome 
structure, known as CNVs. These are deletions or amplifications 
of DNA segments arising from inappropriate chromosomal 
recombination, due to flanking region-specific repeat sequences 
or from highly homologous genes that misalign during meiosis. 
CNVs can be identified using arrayCGH or genomic microarrays 
that assess single-nucleotide polymorphisms (SNPs). The altered 
dosage of contiguous genes included inside CNVs can produce 
new syndromic CHDs, so that several different new genomic 
conditions have been identified.
Duplication 22q11.2 Syndrome
The duplication 22q11.2 syndrome is the reciprocal product of 
the 3-Mb chromosomal region deleted in DiGeorge/velocardi-
ofacial syndrome (between LCRA and LCRD) (5, 6). The most 
frequently reported features are mental retardation, learning 
difficulties, ADHD, growth retardation, and facial anomalies. 
CHDs, visual and hearing impairment, seizures, microcephaly, 
ptosis, and urogenital abnormalities have also been reported. 
The prevalence of CHD in duplication 22q11.2 is lower in com-
parison to that of deletion 22q11.2, and the spectrum of CHDs 
wider, including defects belonging to different pathogenetic 
pathways (septal defects, conotruncal heart defect, and left-sided 
obstructive lesions). The molecular basis leading to CHD is to be 
elucidated, considering the overexpression of the TBX1 gene and 
the possible interaction with other genes inside and outside the 
22q11.2 chromosomal region.
Distal 22q11.2 Deletion Syndrome
The distal 22q11.2 deletion syndrome is a new genomic disorder 
mapping at the telomeric end of the common DiGeorge/22q11.2 
deleted region (7). Clinical features of the 22q11.2 distal deletion 
syndrome include developmental delay, facial anomalies, low 
birth weight, skeletal anomalies, and CHDs. Anatomic types of 
CHD include ventricular septal defects, truncus arteriosus, double 
outlet right ventricle, aortic anomalies, and left ventricular non-
compaction (8). Particularly, left ventricular non-compaction 
with aortic valve anomalies has been recently reported as useful 
diagnostic marker for the syndrome (9). Genes functionally 
interacting with TBX1, but mapping distal to this gene, such 
as CRKL and ERK2/MAPK1, have been proposed as candidate 
to CHD in this syndrome, in particular haploinsufficiency of 
MAPK1 gene, located between LCR22-4 and LCR22-5 (8). It has 
been observed that smaller deletions seem to be associated with 
the more complex CHDs, particularly those involving LCR22-4 
to LCR22-5 and LCR22-4 to LCR22-6.
Deletion and Duplication 1q21.1
Microdeletion 1q21.1 (del 1q21.1) and the reciprocal microdupli-
cation 1q21.1 (dup 1q21.1) are genomic disorders characterized 
by developmental delay, dysmorphic features, and congenital 
malformations (10). CHD is a major feature of deletion 1q21.1 
and has been occasionally reported in duplication 1q21.1 (10–12). 
The anatomic types of CHD diagnosed in deletion 1q21.1 are het-
erogeneous, including mainly left-sided obstructions (40%), as 
aortic coarctation, bicuspid aortic valve, and subaortic stenosis, 
but also septal defects (27%) and conotruncal anomalies (20%). 
Our group has reported a family segregating deletion 1q21.1 in 
three members, two of whom had CHD, including syndromic 
atrial septal defect, pulmonary valve stenosis, and muscular 
ventricular septal defects, and the maternal uncle of this proband 
3Digilio and Marino Genetics of CHD
Frontiers in Pediatrics | www.frontiersin.org December 2016 | Volume 4 | Article 120
with non-syndromic pulmonary valve stenosis (12). This finding 
prompted the investigation of the role of recurrent rearrangements 
of chromosome 1q21.1 region in the pathogenesis of pulmonary 
valve stenosis. The results of this study were that duplication 
1q21.1 was detected in a single sporadic non-syndromic patient. 
Soemedi et al. (13) studied recurrent rearrangements of chromo-
some 1q21.1 in 2436 patients with CHD, demonstrating that 
duplication 1q21.1 was more common in cases with tetralogy of 
Fallot, while deletion 1q21.1 was associated with CHDs different 
from tetralogy of Fallot.
Inside the 1q21.1 chromosomal region are mapping genes 
important for CHD development. At least two of these genes, 
AMP-activated protein kinase (AMPK) and GJA5 (Cx40), are 
expressed in the cardiac tissue. Mutations in AMPK are occurring 
in a subset of subjects affected by familial hypertrophic cardiomy-
opathy (14). Cx40 gene imbalances could account for structural 
cardiac defects in del 1q21.1. In fact, Cx40 haploinsufficient mice 
can have different types of CHD, including ventricular septal 
defect, tetralogy of Fallot, and aortic arch abnormalities (15). 
Recently, GJA5 gene has been demonstrated to be a susceptibility 
gene for non-syndromic tetralogy of Fallot in humans (13, 16).
Deletion 1p36 Syndrome
Deletion 1p36 is one of the most common genomic disorders, 
and the second most common deletion syndrome, character-
ized by intellectual disability, epilepsy, CHD, and characteristic 
dysmorphic facial features (17). CHD is diagnosed in about 50% 
of these patients, which includes cardiomyopathy and a high 
prevalence of left ventricular non-compaction (17, 18). This type 
of cardiomyopathy is characterized by prominent left ventricular 
trabeculae and deep intratrabecular recesses. Associated extra-
cardiac anomalies occur in 14–66% of the patients in different 
series, in the setting of syndromic, metabolic, and neuromuscular 
disorders (19). Interestingly, the transcription factor PRDM16, 
mapping inside the critical region of 1p36 syndrome, has been 
established to be linked to a proportion of non-syndromic left 
ventricular non-compaction patients (20).
A specific association has been noted also between Ebstein 
anomaly, an uncommon CHD characterized by downward 
displacement of the tricuspid valve into the right ventricle, and 
deletion 1p36 syndrome (21).
New GeNeS FOR MONOGeNiC 
SYNDROMeS wiTH CHD
Adams–Oliver Syndrome
Adams–Oliver syndrome is a rare developmental disorder 
characterized by the combination of aplasia cutis congenita of 
the scalp vertex and terminal transverse limb defects (22). In 
addition, vascular anomalies and CHD are frequently observed. 
CHDs have been estimated to be present in 20% of individuals 
with Adams–Oliver syndrome, including various anatomic types 
with a specific association with left-sided obstructive lesions (23). 
The syndrome was known to be etiologically heterogeneous, since 
mutations in four different genes (ARHGAP31, RBPJ, DOCK6, 
and EOGT) have been detected in about 10% of individuals with 
this syndrome, particularly without cardiac involvement (22). 
Recently, heterozygous variants in NOTCH1 gene, belonging 
to the Notch signaling pathway, have been shown to be related 
to Adams–Oliver syndrome with CHD (24, 25). It has been 
proposed that the limb and scalp defects might also be due to a 
vasculopathy in NOTCH1-related AOS. Interestingly, germline 
NOTCH1 variants affecting diverse domains of the protein can 
be associated with autosomal dominant non-syndromic CHDs 
affecting the left ventricular outflow tract, most commonly bicus-
pid aortic valve, with an additional frequent feature of adult-onset 
precocious aortic valve calcification (26).
Kabuki Syndrome
Kabuki syndrome is a genetic disease causing developmental 
delay and congenital malformations with specific facial features. 
Left-sided cardiac obstructive lesions are known to be the first 
type of CHDs for frequency in these patients, although septal and 
conotruncal defects can also be detected (27). The involvement 
of X chromosome has been previously suspected in order to 
justify the high prevalence of left-sided defects (27). Since the 
identification of MLL2 gene mutations as the primary cause of 
this syndrome (28), the involvement of the second gene has been 
discovered (29). In fact, de novo partial or complete deletions 
of an X chromosome gene, KDM6A, which encodes a histone 
demethylase that interacts with MLL2, so as heterozygous gene 
mutations of the same gene have been diagnosed in patients 
with Kabuki phenotype, identifying KDM6A as another cause of 
Kabuki syndrome.
Noonan Syndrome
Noonan syndrome and related disorders, including Leopard, 
cardiofaciocutaneous, and Costello syndromes (the so-called 
RASopathies), are causally linked to germline mutations in a 
number of genes coding transducers and modulatory proteins 
participating in the RAS–MAP kinase (MAPK) signaling path-
way (30). Clinical features include dysmorphic features, CHDs, 
postnatal growth retardation, ectodermal and skeletal defects, 
and variable cognitive deficits (30). CHDs occur in approxi-
mately 60–90% of patients affected by one of these RASopathies, 
depending on the mutated genes. Pulmonary valve stenosis and 
hypertrophic cardiomyopathy are the most common defects dis-
playing a distinct association with the RASopathies (31). Noonan 
syndrome and other RASopathies are genetically heterogeneous, 
and mutations in the PTPN11, SOS1, KRAS, RAF1, BRAF, 
SHOC2, MEK1, and MEK2 genes have been documented (30). 
A new gene for RASopathies is being discovered every 6 months 
in the last years, and after the identification of the additional 
genes NRAS (32), CBL (33), RIT1 (34), and LZTR1 (35) the 
percentage of molecularly confirmed Noonan syndrome patients 
is 90%. CHDs associated with mutations is these new genes are 
the classic ones. The prevalence of CHDs in patients with RIT1 
gene is particularly high (90%) (36).
In addition, it has been confirmed by molecular diagnosis 
that AVCD is a part of the phenotypic spectrum of CHDs 
found in patients with RASopathies, in particular those caused 
by PTPN11 and RAF1 gene mutations, as the third most 
common CHD (37). Partial atrioventricular canal associated 
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with left-sided obstructions or pulmonary valve stenosis or 
hypertrophic cardiomyopathy should be regarded as markers 
for RASopathies.
MODiFieR GeNeS FOR SYNDROMiC 
CHDs
The etiology of intrafamilial phenotypical variability of genetic 
syndromes is currently not known. The variable expressivity 
and reduced penetrance of CHDs is likely influenced by genetic 
factors. In deletion 22q11.2 (DiGeorge/velocardiofacial) 
syndrome, it has been suspected that genetic variants lying 
outside of the 22q11.2 region are influencing the development 
of CHD. CNVs have been extensively studied. Recent results 
have shown that CNVs of the glucose transporter gene SLC2A3, 
particularly duplications, can increase the risk to born with 
a CHD (38). Murine SLC2A3 is expressed in the pharyngeal 
apparatus and cardiac outflow tract during cardiac morpho-
genesis. In humans, individuals with a duplication of SLC2A3 
in the absence of deletion 22q11.2 do not present with CHDs, 
and the SLC2A3 is often transmitted from a parent with normal 
heart and not carrying deletion 22q11.2, indicating that both 
mutations may be required for the manifestation of a CHD. 
This finding supports a possible “two-hit” model. In  fact,  it 
appears  likely that there may be an epistatic interaction 
between the SLC2A3 duplication and dosage sensitive genes 
in the 22q11.2 deleted region that increase the likelihood of a 
structural cardiac defect.
NON-SYNDROMiC CHDs
It is thought that the etiology of the great majority of non-
syndromic CHDs can be explained by a “multifactorial” model of 
inheritance (39). This mechanism of inheritance is reconducted 
to a genetic predisposition interacting with an environmental 
trigger. The genetic predisposition is presumed to by polygenic, 
due to the small additive effects of many genes. However, a 
single locus or a small number of loci are also considered to be 
implicated.
CNvs AND NON-SYNDROMiC CHD
Recent experimental studies have identified multiple CNVs 
contributing to non-syndromic CHD. Pathogenetic de novo 
CNVs have been reported in patients with tetralogy of Fallot, 
AVCD, and left-sided lesions (40–44). According to the results 
of these studies, it has been estimated that 5–10% of sporadic 
non-syndromic CHD can be due to a rare CNV. Some CNVs are 
mapping in chromosomal regions previously known to contain 
genes pathogenetically related to CHDs. In fact, recurrent CNVs 
included chromosome 8p23.1 including the GATA4 gene or 
chromosomes 20p12.2 and 9q34.3 where two genes for Alagille 
syndrome, JAG1, and NOTCH1 are included. The distinction 
between pathogenetic CNVs and benign polymorphic variants 
is not always clear. Filtering genes mapping in CNV regions can 
probably in the future add knowledge about new genes for non-
syndromic CHDs.
MONOGeNiC iNHeRiTANCe iN  
NON-SYNDROMiC CHDs
Most cases of CHD occur sporadically without a strong family 
history. Nevertheless, Mendelian monogenic transmission has 
also been evidenced for some types of CHDs, including atrial sep-
tal defects, AVCD, and left-sided obstructive lesions. Monogenic 
inheritance has been demonstrated particularly in pedigrees 
with a clear familial recurrence of the defect. Nevertheless, the 
number of identified genes for non-syndromic CHDs is at this 
time limited, and each of the identified genes has been shown to 
be implicated only in a small proportion of CHD (45–51).
Low penetrance has been demonstrated in some pedigrees, 
when a mutation in a CHD gene in an affected proband is segre-
gating from an unaffected parent (52).
Additive effect of multiple genes can also be considered in 
some families (53). In fact, it has been observed that mutations in 
different genes segregating in different manner in relatives can be 
causally related to CHD, which argues for an oligogenic complex 
mode of inheritance.
CLiNiCAL iMPLiCATiONS
Early and precise genetic diagnosis of patients with CHD is useful 
for clinical management of children and genetic counseling for 
families. In fact, possible associated extracardiac anomalies can 
be monitored and treated. The patients can be followed accord-
ingly to multidisciplinary protocols and guidelines specific for the 
syndrome (54, 55).
In regard to cardiac risk factors is emerging that specific 
perioperative protocols may reduce the mortality and morbidity 
of CHDs in syndromic patients (56). Surgical prognosis of CHDs 
in some specific syndromes has been studied. Results are showing 
that surgical risks for complete and partial atrioventricular canal 
in Down syndrome are not increased, with the exception of the 
risk for pulmonary hypertension (56, 57). In regard to conotrun-
cal heart defects, microdeletion 22q11.2 syndrome is not a risk 
factor, and increased surgical mortality is described only for 
patients with pulmonary atresia with ventricular septal defect 
(58). Other complex syndromes, such as VACTERL association, 
can have a negative impact on the surgical prognosis (58).
CONCLUSiON
Multiple parallel diagnostic approaches are currently used for the 
identification of the potential loci etiologically related to CHDs, 
and recent advances in genetic technologies have improved the 
possibility to detect new genes and chromosomal regions for CHDs. 
With these methods, several causes of syndromic and isolated CHDs 
have been discovered, although much work still remains to be done, 
particularly in respect to non-syndromic CHD, since knowledge of 
their underlying genetic mechanisms is at present rather limited, 
due to the multifactorial and complex mode of inheritance.
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